Rice Hall James & Associates’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-32,971
| Closed | -$8.49M | – | 320 |
|
|
2021
Q2 | $8.49M | Sell |
32,971
-4,768
| -13% | -$1.32M | 0.3% | 73 |
|
|
2021
Q1 | $11.3M | Sell |
37,739
-153
| -0.4% | -$47.6K | 0.37% | 64 |
|
|
2020
Q4 | $9.66M | Sell |
37,892
-1,637
| -4% | -$423K | 0.34% | 63 |
|
|
2020
Q3 | $9.84M | Buy |
39,529
+1,807
| +5% | +$568K | 0.4% | 62 |
|
|
2020
Q2 | $13.1M | Sell |
37,722
-1,180
| -3% | -$368K | 0.56% | 53 |
|
|
2020
Q1 | $10.4M | Sell |
38,902
-893
| -2% | -$276K | 0.58% | 50 |
|
|
2019
Q4 | $12.9M | Sell |
39,795
-1,383
| -3% | -$401K | 0.44% | 91 |
|
|
2019
Q3 | $11.3M | Sell |
41,178
-822
| -2% | -$301K | 0.4% | 96 |
|
|
2019
Q2 | $22.4M | Sell |
42,000
-2,691
| -6% | -$1.35M | 0.74% | 39 |
|
|
2019
Q1 | $22.5M | Buy |
44,691
+1,424
| +3% | +$844K | 0.73% | 40 |
|
|
2018
Q4 | $21.3M | Buy |
43,267
+12,998
| +43% | +$7.85M | 0.78% | 38 |
|
|
2018
Q3 | $27.7M | Sell |
30,269
-723
| -2% | -$617K | 0.99% | 26 |
|
|
2018
Q2 | $22.7M | Buy |
30,992
+259
| +0.8% | +$299K | 0.83% | 32 |
|
|
2018
Q1 | $49M | Sell |
30,733
-37,889
| -55% | -$48.8M | 1.91% | 7 |
|
|
2017
Q4 | $61.5M | Sell |
68,622
-13,865
| -17% | -$8.2M | 2.42% | 1 |
|
|
2017
Q3 | $29.7M | Sell |
82,487
-3,494
| -4% | -$1.09M | 1.31% | 10 |
|
|
2017
Q2 | $25.2M | Buy |
85,981
+17,638
| +26% | +$5.1M | 1.1% | 18 |
|
|
2017
Q1 | $24.1M | Sell |
68,343
-245
| -0.4% | -$55.1K | 1.17% | 10 |
|
|
2016
Q4 | $12.6M | Sell |
68,588
-1,262
| -2% | -$257K | 0.64% | 71 |
|
|
2016
Q3 | $18M | Buy |
69,850
+7,654
| +12% | +$1.97M | 0.94% | 44 |
|
|
2016
Q2 | $13.3M | Buy |
62,196
+855
| +1% | +$191K | 0.76% | 63 |
|
|
2016
Q1 | $12.7M | Buy |
61,341
+1,372
| +2% | +$264K | 0.73% | 58 |
|
|
2015
Q4 | $15.2M | Buy |
59,969
+25,171
| +72% | +$5.18M | 0.87% | 50 |
|
|
2015
Q3 | $5.72M | Buy |
34,798
+2,787
| +9% | +$493K | 0.37% | 74 |
|
|
2015
Q2 | $6.01M | Sell |
32,011
-3,161
| -9% | -$544K | 0.35% | 78 |
|
|
2015
Q1 | $5.8M | Buy |
35,172
+4,499
| +15% | +$925K | 0.34% | 84 |
|
|
2014
Q4 | $7.13M | Buy |
30,673
+4,990
| +19% | +$1.07M | 0.43% | 61 |
|
|
2014
Q3 | $4.65M | Buy |
25,683
+13,594
| +112% | +$2.6M | 0.32% | 71 |
|
|
2014
Q2 | $2.33M | Buy |
12,089
+3,823
| +46% | +$676K | 0.16% | 175 |
|
|
2014
Q1 | $1.5M | Buy |
8,266
+3,680
| +80% | +$728K | 0.11% | 209 |
|
|
2013
Q4 | $781K | Buy |
4,586
+2,883
| +169% | +$465K | 0.06% | 234 |
|
|
2013
Q3 | $267K | Sell |
1,703
-359
| -17% | -$66.4K | 0.03% | 262 |
|
|
2013
Q2 | $357K | Buy |
+2,062
| New | +$316K | 0.04% | 242 |
|
Other funds holding NKTR
MC
BG
Rice Hall James & Associates's NKTR Position: Q3 2021 in Review
Rice Hall James & Associates sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 32,971 shares — an estimated $8.49M sold.
Rice Hall James & Associates first reported a position in NKTR in Q2 2013 and held it in 33 quarters. The position peaked at $61.5M in Q4 2017. 240 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.
- Rice Hall James & Associates reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
- Rice Hall James & Associates sold 32,971 Nektar Therapeutics shares in Q3 2021, an estimated $8.49M.
- Rice Hall James & Associates first reported a position in Nektar Therapeutics in Q2 2013 and held it in 33 quarters.
- Rice Hall James & Associates's Nektar Therapeutics position peaked at $61.5M in Q4 2017.
- 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.
Based on Rice Hall James & Associates's 13F filing for Q3 2021, filed 9 Nov 2021.